AstraZeneca: lung cancer drug wins approval in China
(CercleFinance.com) - AstraZeneca's Tagrisso cancer drug has won approval in China, the Anglo-Swedish drugmaker said on Wednesday.
The company said it has received marketing authorisation from China's National Medical Products Administration for Tagrisso as a first-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose tumours have the genetic mutations of epidermal growth factor receptor (EGFR).
Approximately 30%-40% of non-small cell lung cancer patients in China are diagnosed with an EGFR mutation, more than in any other country in the world.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The company said it has received marketing authorisation from China's National Medical Products Administration for Tagrisso as a first-line treatment for adults with locally-advanced or metastatic non-small cell lung cancer (NSCLC), whose tumours have the genetic mutations of epidermal growth factor receptor (EGFR).
Approximately 30%-40% of non-small cell lung cancer patients in China are diagnosed with an EGFR mutation, more than in any other country in the world.
Copyright (c) 2019 CercleFinance.com. All rights reserved.